ALPROLIX KIT

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

RECOMBINANT HUMAN COAGULATION FACTOR IX, FC FUSION PROTEIN

Inapatikana kutoka:

SANOFI-AVENTIS CANADA INC

ATC kanuni:

B02BD04

INN (Jina la Kimataifa):

COAGULATION FACTOR IX

Kipimo:

4000UNIT

Dawa fomu:

KIT

Tungo:

RECOMBINANT HUMAN COAGULATION FACTOR IX, FC FUSION PROTEIN 4000UNIT

Njia ya uendeshaji:

INTRAVENOUS

Vitengo katika mfuko:

5ML

Dawa ya aina:

Schedule D

Eneo la matibabu:

HEMOSTATICS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0155510006; AHFS:

Idhini hali ya:

APPROVED

Idhini ya tarehe:

2020-09-25

Tabia za bidhaa

_ALPROLIX, Coagulation Factor IX (Recombinant), Fc Fusion Protein _
_Page 1 of 42 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
ALPROLIX
®
Coagulation Factor IX (Recombinant), Fc Fusion Protein
Lyophilized Powder for Solution
250, 500, 1000, 2000, 3000 and 4000 IU/vial
Antihemorrhagic Blood Coagulation Factor IX
sanofi-aventis Canada Inc.
2905 Place Louis R.-Renaud
Laval, Quebec H7V 0A3
Date of Initial Authorization:
March 20, 2014
Date of Revision:
November 5, 2021
SUBMISSION CONTROL NUMBER: 246919
_ _
_Alprolix Coagulation Factor IX (Recombinant), Fc Fusion Protein _
_Page 2 of 42_
RECENT MAJOR LABEL CHANGES
1 INDICATIONS
09/2021
7 WARNINGS AND PRECAUTIONS, 7.1.3 Pediatrics
09/2021
TABLE OF CONTENTS
RECENT MAJOR LABEL
CHANGES............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
..........................................................................................................
4
1.2
Geriatrics...........................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
4
DOSAGE AND
ADMINISTRATION.................................................................................
4
4.1
Dosing Considerations
.......................................................................................
4
4.2
Recommended Dose and Dosage
Adjustment..................................................... 4
4.4
Administration...................................................................................................
7
5
OVERDOSAGE
....